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http://dx.doi.org/10.1016/j.stemcr.2016.06.003SUMMARYWiskott-Aldrich syndrome (WAS) is an X-linked primary immunodeficiency disease caused by mutations in the gene encoding theWAS
protein (WASp). Here, induced pluripotent stem cells (iPSCs) were derived from aWAS patient (WAS-iPSC) and the endogenous chromo-
somalWAS locuswas targetedwith awtWAS-2A-eGFP transgene using zinc finger nucleases (ZFNs) to generate correctedWAS-iPSC (cWAS-
iPSC).WASp andGFPwere first expressed in the earliest CD34+CD43+CD45 hematopoietic precursor cells and later in all hematopoietic
lineages examined. Whereas differentiation to non-lymphoid lineages was readily obtained from WAS-iPSCs, in vitro T lymphopoiesis
fromWAS-iPSC was deficient with few CD4+CD8+ double-positive and mature CD3+ T cells obtained. T cell differentiation was restored
for cWAS-iPSCs. Similarly, defects in natural killer cell differentiation and functionwere restored on targeted correction of theWAS locus.
These results demonstrate that the defects exhibited byWAS-iPSC-derived lymphoid cells were fully corrected and suggests the potential
therapeutic use of gene-corrected WAS-iPSCs.INTRODUCTION
Wiskott-Aldrich syndrome (WAS) is a severe X-linked pri-
mary immunodeficiency resulting from mutations in the
WAS gene; WAS encodes a hematopoietic-specific and
developmentally regulated cytoplasmic protein (WASp).
WASp is a key regulator of the actin cytoskeleton, specif-
ically regulating actin polymerization and formation of
immunological synapses. Within the immune system,
WASp deficiency results in well-documented functional
defects in mature lymphocytes such as reduced antigen-
specific proliferation of T cells and significantly reduced
cytotoxic activity by natural killer (NK) cells when exposed
to tumor cell lines (Orange et al., 2002).
Transplantation of hematopoietic stem cells (HSCs) rep-
resents a potential therapeutic approach for a variety of
hematological disorders. Success in treating WAS via lenti-
viral-mediated gene delivery has recently been reported
(Aiuti et al., 2013; Hacein-Bey Abina et al., 2015).
Although no leukemogenic events were reported in up
to 3 years following delivery of gene-modified CD34+Stem C
This is an open access article under the Ccells, it remains difficult to predict whether any of the
unique integration sites (e.g., 10,000 per treated child
in Aiuti et al. [2013]) will result in adverse consequences
in the longer term as occurred in the original WAS retro-
viral gene-therapy trial (Braun et al., 2014). Thus, develop-
ment of site-specific targeting strategies for treatment of
WAS is warranted.
In this study, we wished to assess whether targeted gene
editing of WASp-deficient induced pluripotent stem cells
(iPSCs) would result in functional correction of the derived
hematopoietic progeny. WAS can be caused by a diversity
of mutations distributed across all 12 exons. To provide a
gene correction solution potentially applicable to most, if
not all, WAS patient cells, we used zinc finger nuclease
(ZFN)-mediated, site-specific, homology-directed repair
(HDR) to target the integration of a corrective WAS gene
sequence into the endogenous WAS chromosomal locus.
We hypothesized that utilizing the endogenous WAS
promoter, the natural WAS chromatin environment, and
transcription regulatory signals, would provide for a phys-
iologically appropriate WAS transgene expression.ell Reports j Vol. 7 j 139–148 j August 9, 2016 j ª 2016 The Authors. 139
C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
RESULTS
Derivation and Characterization of WAS-iPSCs
Skin fibroblasts were obtained from aWAS patient carrying
the 1305 insG WAS mutation. This single-base-pair inser-
tion in exon 10 of theWAS genewould be predicted to yield
aWAS protein (WASp) frameshifted at amino acid 424, out-
of-frame throughout the C-terminal VCA (verprolin ho-
mology, cofilin homology, acidic) domains critical for
WASp-dependent actin polymerization and immunolog-
ical synapse formation, and to conclude in a premature
termination at position 493. Patients with the 1305 insG
WAS mutation exhibit negligible WASp expression in he-
matopoietic cells, likely due to instability or degradation
of the protein (Wada et al., 2003).
Following reprogramming, we verified the WAS 1305
insG mutation in WAS-iPSC clones, and confirmed charac-
teristic pluripotent stem cell antigen expression, a normal
karyotype, and pluripotency (Figures S1A–S1D). Quantita-
tive transcriptional profiling of WAS-iPSCs revealed a
gene expression pattern highly similar to human embry-
onic stem cells (hESCs) (line WA09) (Figure S1E).Endogenous Targeted Integration: WAS-iPSC Gene
Correction
WAS-iPSCs were corrected via ZFN-mediated HDR as
shown in Figure 1A. The targeting strategy was such that
successful HDR-mediated targeted integration (TI) of the
WAS exon 2–12 cDNA (WAS2–12) within intron 1 would
result in normal transcriptional initiation at exon 1
(directed by the endogenous upstream transcriptional reg-
ulatory sequences); splicing from the splice donor at the
end of exon 1 to the splice acceptor at the start of the
WAS2–12 cDNA to yield theWAS-2A-GFPmRNA; the inclu-
sion of GFP in the WAS2–12-2A-GFP cassette was to enable
tracking of WASp-expressing cells. A loxP-flanked pgk-
puroTK-selectable cassette was inserted just downstream
of the transgene sequences in order to permit puromycin-
mediated selection of initial clones as well as subse-
quent fialuridine (FIAU)-mediated selection of Cre-excised
clones.
Successfully targeted puromycin-resistant clones were
first identified by PCR amplification utilizing primers
located outside the donor sequences and further confirmed
by DNA sequencing (data not shown). Southern blot anal-
ysis utilizing the pgk-puroTK sequences as probe, confirmed
the intended TI within the WAS locus, and the absence of
off-target integrations (Figure S2A). Transient expression
of Cre-recombinase, followed by FIAU selection, was uti-
lized to excise the pgk-puroTK-selection cassette. The cor-
rected WAS (cWAS) iPSCs, both prior to and following
Cre-mediated excision of the selection cassette, retained140 Stem Cell Reports j Vol. 7 j 139–148 j August 9, 2016a normal karyotype (Figure S2B) and pluripotency (Fig-
ure S2C). Comparative genomic hybridization (CGH) and
whole-exome sequencing were performed on WAS and
cWAS-iPSCs to determine whether the targeted correction
methodology resulted in unanticipated changes to the
chromosomal DNA. The results of these analyses are pre-
sented in Tables S1–S3. These data indicate that the
cWAS-iPSCs were generated without any apparent delete-
rious mutation that could cloud the interpretation of
further experiments.
Derivation and Characterization of Hematopoietic
Progenitor Cells from WAS and cWAS-iPSCs
SinceWASp is normally expressed in all hematopoietic cells
including the CD34+ hematopoietic progenitor cells
(HPCs), we examined HPCs derived from the patient
WAS- or cWAS-iPSCs; WA01 or WA09 hESCs carrying
wild-type (WT)WASwere used interchangeably as controls.
Differentiation of iPSCs progressed from CD34+CD43
endothelial cells to CD34+CD43+ cells (CD43 is expressed
early on hematopoietic cells) and finally to CD34+CD45+
HPCs, similar to cultures initiated by WAS- and cWAS-
iPSCs, and highly similar to the patterns exhibited by
control hESCs (Figure 1B). The absolute numbers of the
specific cell populations (CD34+CD43, CD34+CD43+,
and CD34+CD43+CD45+) obtained per embryoid body
(EB) demonstrates that the WAS 1305 insG mutation does
not adversely affect the emergence/development of
CD34+ HPCs from hemogenic endothelium when com-
pared with cWAS (Figure 1C) (p = 0.502, not significant
[NS]). Further differentiation ofWAS-derived CD34+CD43+
CD45+/ HPC toward myeloid, erythroid, and megakaryo-
cytic lineages revealed no major differentiation defects
compared with cWAS or hESC (Figure 1D).
Restoration of WASp Expression in cWAS-iPSC-
Derived Hematopoietic Cells
In order to assess restoration of WASp expression in the
cWAS-iPSC-derived cells, we first assayed GFP expression
in the in vitro differentiation cultures. GFP expression,
albeit at low levels, was clearly present in cWAS-iPSC-
derived CD34+CD43+CD45 hematopoietic progenitors
and in all hematopoietic lineages including myeloid,
erythroid, and megakaryocytic lineages (Figure 2A). GFP
expression was very weak to absent in cWAS-iPSC-
derived CD34+KDR+CD43CD45 endothelial cells (Fig-
ure 2A). There was no indication of differential GFP
expression in CD34+KDR+CD43CD73hemogenic versus
CD34+KDR+CD43CD73+ non-hemogenic endothelial
cells (Figure S3A).
RT-PCR for WAS sequences was performed for the WAS-
and cWAS-iPSC-derived CD34+CD43+ HPCs. The native
WASp transcript including the 30 UTR was present in
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Figure 1. Targeted, ZFN-Mediated Correction of WAS-iPSCs and Derivation of Hematopoietic Progeny
(A) Targeted integration of the WAS-2A-GFP transgene into the endogenous mutant WAS locus.
(B) Flow cytometric analysis of in vitro hematopoietic differentiation assays showing efficient generation of hematopoietic pro-
genitors (CD34+CD43+ and CD34+CD45+); data shown are of day 12 cultures from a representative experiment initiated with spin EBs
from WA01 hESCs, WAS-iPSCs, and cWAS-iPSCs. Expression of CD34/CD45 is shown in the lower panels after gating on the CD43+ cells.
Numbers shown are the percentage of analyzed cells in each region. Regions were set based on control staining with isotype control
antibodies.
(C) Quantitative analysis of the number of CD34+CD43 endothelial cells, CD34+CD43+ hematopoietic progenitor cells (HPCs), and
CD34+CD45+ HPCs generated per EB. Each data point represents a separate experiment. N (number of differentiated experimental samples;
biological replicates) for CD34+CD43 equals 9, 13, and 8 for hESC, WAS, and WAS, respectively. Similarly, for CD34+CD43+ N equals 11, 13,
and 11, respectively, and for CD34+CD43+CD45+ N equals 8, 8, and 7, respectively. Statistical significance was assessed via the Mann-
Whitney U test.
(D) Flow cytometric analysis of in vitro derivation of myeloid (CD45+CD33+), erythroid (CD45CD235a+), and megakaryocytic/platelet
(CD45CD41+) progeny. Data are of day 12 cultures from a representative experiment.peripheral blood mononuclear cells (PBMCs) and in WAS-
and hESC-derived blood cells, but not in cWAS-derived
cells (Figure 2B). In contrast, cWAS-derived hematopoietic
cells expressed the transgenic transcript that correlated
with expression of the GFP transcript (Figure 2B).
Sequencing confirmed that the WAS mRNA expressed by
the cWAS CD34+CD43+ cells was of a WT sequence (i.e.,
not the mutant 1305 insG) (Figure 2C), and derived fromthe integrated WAS2–12 transgene (i.e., included a silent
C > A substitution at position 995) (Figure 2C).
WASp expression in CD34+CD43+ cells was directly as-
sessed by western blot and fluorescence-activated cell sort-
ing (FACS) analysis. Western blot analysis confirmed the
absence of WASp in WAS CD34+CD43+ progenitors but
detectable WASp in cWAS CD34+CD43+ progenitors (Fig-
ure 2D). As expected, the cWAS-iPSC-derived progenitors,Stem Cell Reports j Vol. 7 j 139–148 j August 9, 2016 141
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Figure 2. Expression of the WAS-2A-GFP Transgene in cWAS-iPSC-Derived Hematopoietic Cells
(A) Assessment of GFP expression in various cWAS-iPSC-derived cell populations. WA01- and WAS-iPSC-derived cells are shown as controls.
RMFI (the ratio of the mean fluorescence intensity [MFI] for cWAS-iPSC-derived cells to the MFI for WAS-iPSC-derived cells) is shown for
each cell type.
(B) Quantitative RT-PCR analysis, expressed asDD Ct of endogenousWAS and transgene (WAS, GFP) expression in CD34+CD43+ HPCs. Shown
are the mean and SD of the mean for a total of two experimental cultures, each analyzed in duplicate by quantitative RT-PCR. Endogenous
WAS expression was normalized to PBMCs. Transgene WAS and EGFP expression was normalized to cWAS HPCs.
(C) Sequence analysis ofWAS cDNA in CD34+CD43+ HPCs. RT-PCR primers were designed to amplifyWAS cDNA, irrespective of whether it was
endogenous or transgenic.
(D) Western blot analysis of WASp expression in CD34+CD43+ HPCs; human PBMCs served as positive control. Immunostaining for calnexin
demonstrated relatively equal loading of protein.in comparison with healthy PBMCs and hESC-derived
progenitors, expressed a WASp of slightly higher molecu-
lar weight resulting from the additional 19 2A amino
acids at the carboxyl end (Figure 2D). Anti-WASp immu-
nostaining of CD34+CD43+ cells gave evidence for a
low level of WASp expression in cWAS progenitors, consis-142 Stem Cell Reports j Vol. 7 j 139–148 j August 9, 2016tent with the low GFP expression level (Figure S3B); this
level of WASp expression was reproducible and just
slightly less than that seen for hESC-derived progenitors.
Together, these data demonstrate restoration of physiolog-
ical expression levels of WASp in cWAS hematopoietic
progenitors.
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Figure 3. In Vitro Derivation and Functional Assessment of CD56+ NK Cells from WAS and cWAS-iPSCs
(A) Flow cytometric analysis of CD56+ NK cells obtained from EB-derived CD34+CD43+ HPCs plated onto OP9-DL1 feeder layers. These data
are of day 13 cultures from a representative experiment. The HPC-derived CD56+ NK cells also express early lymphoid marker CD7 and NK
marker CD94.
(B) Quantitative analysis of the number of CD56+ NK cells generated per EB in experiments performed with either OP9-DL1 or OP9-DL4
feeders (N = 7; five independent differentiation experiments for hESC, WAS, and cWAS in which three experiments were sampled at a single
time point and two experiments were sampled at two time points).
(C) Assessment of GFP expression in cWAS-iPSC-derived NK cells. WA09 hESC- and WAS-derived cells are shown as controls. RMFI is defined
as in Figure 2A.
(D) Sequence analysis of WAS cDNA in cWAS CD56+ NK cells. The sequence confirms expression of the transgene (995C>A [marked with
arrowhead] and absent 1305 insG).
(E) Western blot analysis of WASp expression in cWAS-derived CD56+ NK cells; NK cells generated from healthy donor umbilical cord blood-
derived iPSCs served as control. Calnexin served as control for protein loading.
(F) Functional assessment of IFN-g and TNF-a expression in NK cells after activation. Shown is the intracellular expression IFN-g (top
panels) and TNF-a (bottom panels) by WAS- and cWAS-iPSC-derived CD56+ cells, either unstimulated or stimulated by exposure to K562
cells. WA01 ESC-derived CD56+ cells are shown as control. Indicated is the percentage of NK cells expressing either IFN-g or TNF-a upon
stimulation.cWAS-iPSC-Derived Hematopoietic Progenitors
Develop into NK Cells that Exhibit WASp-Dependent
Function
WAS- and cWAS-iPSC-derived HPCs, as well as control
hESC-derived progenitors, were further differentiated in
culture conditions developed for NK cell differentiation.Whereas CD56+ NK cells were readily obtained from
cWAS- andhESC-derived progenitors (evidenced by pheno-
typic CD56+CD7+ cells and CD56+CD94+ cells) (Figure 3A),
WAS-derived progenitors yielded a significantly reduced
number of NK cells (p = 0.007 when compared with
cWAS) (Figures 3A and 3B). This deficiency in NK cellStem Cell Reports j Vol. 7 j 139–148 j August 9, 2016 143
development for WAS progenitors was consistently
observed using either OP9-DL1 (Figure 3A) or OP9-DL4
(data not shown) stromal cells to promote NK cell develop-
ment. As expected for transgene-corrected cells, cWAS-
derived NK cells expressed both GFP (Figure 3C) and the
WAS transgene (Figure 3D). Restoration of WASp expres-
sion was confirmed both by FACS (Figure S4A) and western
blot (Figure 3E).
We were able to expand the culture-generated NK cells
including the few NK cells generated in the WAS-initiated
cultures sufficiently to perform a functional analysis on
these cells. WAS progenitor-derived NK cells exhibited
significant functional deficits in comparison with both
cWAS- and hESC-derived NK cells: upon stimulation with
K562 cells, cWAS- and hESC-derived NK cells upregulated
production of interferon-g (IFNg) and tumor necrosis
factor alpha (TNFa); this response to stimulation was not
exhibited by WAS-derived NK cells (Figure 3F). This
indicates that the defect exhibited by WAS-iPSC-derived
NK cells is functionally restored in transgene WASp-
expressing NK cells. IFNg and TNFa were increased in
both WAS- and cWAS-derived NK cells on WASp-indepen-
dent activation by phorbol myristate acetate/ionomycin
(Figure S4B).
cWAS-iPSC-Derived Progenitors Are Fully Competent
in Generation of T Cells
We previously reported the ability to derive functional
T cells from hESCs (Timmermans et al., 2009). Using this
technique, EB-derived CD34+ cells from cWAS were differ-
entiated along the T/NK lineage in OP9-DL1 cultures (Fig-
ure 4A). Besides CD7CD33+ myeloid and CD7+CD56+
NK cells, CD7+CD5+ early T lineage committed precursors
arise early in these cultures (day 14); these early T cell pre-
cursors differentiate (via CD8 and predominantly via
CD4 single-positive intermediates) to CD5+CD4+CD8+
double-positive cells (days 19 and 33) and finally to
CD3+CD1+CD4+CD8+ double-positive cells (day 33) (Fig-
ure 4A). Only few mature single-positive cells are seen in
these cultures. In Figure 4B, representative plots are shown
from a total of 12–14 independent experiments in which
WA01, WAS, and cWAS were cultured and tested head-to-
head: at day 14 CD5+CD7+ T precursor cells were generated
in all three cultures. However, later, only few CD4+CD8+
double-positive precursors (day 28) and CD3+ cells (day
33) are generated in the WAS culture, whereas these cells
are present in the control hESC WA01 and the cWAS cul-
tures. This deficit in generation of double-positives and
CD3+ T cells was not specific to a single WAS-iPSC clone,
but was exhibited by two other mutant WAS clones exam-
ined. A summary of the data is shown in Figure 4C. Again
the data show no significant difference in generation of
CD5+CD7+ T lineage committed precursors between WAS144 Stem Cell Reports j Vol. 7 j 139–148 j August 9, 2016and cWAS (p = 0.834, NS), although the difference with
WA01 was significant (p = 0.016). The deficit of WAS rela-
tive to cWAS and WA01 was clearly evident in derivation
of both CD4+CD8+ (p = 0.008 and p = 0.013, respectively)
and CD3+ T cells (p = 0.002 and p = 0.05, respectively).
Expression of WASp protein throughout T cell differentia-
tion is evidenced byGFP expression in the various T lineage
populations derived from the cWAS-iPSCs (Figure 4D).
Thus, TI of theWAS transgene inWAS-iPSCs restored devel-
opment of both CD4+CD8+ and CD3+ T cells.DISCUSSION
In this study, we demonstrate the successful, sequence-spe-
cific correction ofWAS-iPSCs via TI of aWAS transgene into
the endogenousWAS locus. We chose to target integration
of the WAS2–12 half-gene into intron 1 of the WAS locus
with a view toward potentially providing correction for
all WAS mutations; for exon 1 mutations, targeted iPSC
clones also incorporating the donor WT exon 1 would be
utilized.
This report provides proof-of-concept data for the poten-
tial utility of WASp-deficient iPSCs corrected using site-
directed gene editing. Correcting theWAS gene mutations
in patient-specific iPSCs versus primary HSCs, has two
distinct advantages. The first potential advantage is the
ability to comprehensively sequence the corrected iPSC
clones to rule out any untoward genetic changes. As a first
step toward this end, we compared the WAS and cWAS-
iPSCs via whole-exome sequencing and CGH to identify
potential consequences of the ZFN-mediated gene editing,
Cre-mediated excision, and/or extended iPSC culture.
Although some differences were observed (e.g., amplifica-
tions or deletions uniquely present in either WAS or
cWAS in Table S1, non-synonymous coding variants in
Table S2), we did not observe any generation of mutations
that we could directly attribute to the ZFN-mediated
gene editing. The second potential advantage is that
transplantation of corrected iPSC-derived HSCs will result
in patients receiving a genetically homogeneous popula-
tion of corrected cells. Derivation of transplantable HSCs
from hESCs/human iPSCs (hiPSCs) remains very ineffi-
cient and challenging (Kaufman, 2009; Slukvin, 2013).
Although recent studies suggest strategies to improve gen-
eration of transplantable HSC from human pluripotent
stem cells (Gori et al., 2015), these studies need to be
confirmed with a demonstration of long-term, multi-line-
age HSC engraftment. Non-random X-inactivation of the
WAS gene in female carriers and somatic reversion suggest
the possibility of a selective advantage in vivo for corrected
blood cells at the level of T cell precursors, common
lymphoid progenitor cells, and perhaps even at a more
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Figure 4. In Vitro Derivation of Precursor and Mature T Cells from WAS and cWAS-iPSCs
(A) Flow cytometric analysis of a cWAS OP9-DL1 culture. On the left, CD7/CD5 plots are shown at days 14, 19, and 33 of culture. On the
right, the phenotype of the cells in each of the four quadrants (1–4) is shown. Note the presence of CD7+CD56+ NK cells in early cultures
(quadrant 4). Note that only CD5+ cells generate CD4+CD8b+ and CD3+ cells (quadrant 1 and 2).
(B) Representative experiment of OP9-DL1 cultures: dot plots of WA01 (hESC), WAS, and cWAS cultures. EB-derived CD34+ cells were plated
into OP9-DL1 feeder layers and sampled for emergence of CD7+CD5+ (day 14, top panels), CD4+CD8b+ (day 28, middle panels), and
CD3+TCRab + and CD3+TCRgd+ (day 33, bottom panels) T cells. For CD7/CD5 and CD4/CD8b dot plots, the quadrants were determined based
on staining with isotype-matched antibody controls. The percentage of cells in each quadrant is shown. For the bottom panels, the circled
populations represent CD3+ cells that are also either TCRab+ (e.g., 2% for hESC) or TCRab (e.g., 0.5% for hESC). Cells with phenotype
CD3+TCRab are assumed to be CD3+TCRgd+.
(C) Quantitative analysis of the number of CD5+CD7+ (day 14), CD4+CD8b+ (day 28), and CD3+ cells (day 33) generated per EB. A total of 13
independent differentiated experimental samples are included for CD5+CD7+ (p values: WAS-cWAS p = 0.834 [NS], WAS-hESC p = 0.016), a
total of 14 for CD4+CD8+ (p values: WAS-cWAS p = 0.008, WAS-hESC p = 0.013), and a total of 12 for CD3+ cells (p values: WAS-cWAS
p = 0.002, WAS-hESC p = 0.05). Included in the WAS data are three experiments performed with a different WAS clone than the cWAS parent
line (triangles).
(D) Assessment of GFP expression in T cell populations. WA01 hESC- and WAS-derived cells are shown as controls.primitive stage (Davis et al., 2008; Wengler et al., 1995).
Thus, it may be sufficient to deliver to patients in-vitro-
generated T cell precursors/progenitors from corrected
iPSC.Interestingly, this study ofWASp-deficient iPSCs, in com-
parison with their corrected cWAS-iPSC counterparts, re-
vealed not only the expected functional defects in certain
iPSC-derived hematopoietic progeny (e.g., NK cells), butStem Cell Reports j Vol. 7 j 139–148 j August 9, 2016 145
also identified potential consequences forWASp deficiency
in T and NK development. There is prior evidence from
both WAS patients and WAS knockout mice, that WASp
deficiency may adversely affect the development of
lymphoid cells. Relative to healthy individuals, WAS pa-
tients already at a very early age demonstrate reduced
numbers of peripheral blood T lymphocytes, including
naive T cells (Park et al., 2004). These findings led Park
et al. to propose that WASp was important in the initial
development and maturation of lymphocytes. Studies of
WAS knockout mice (Snapper et al., 1998; Zhang et al.,
1999) have also identified a significantly reduced number
of peripheral blood T lymphocytes. Importantly, Zhang
et al. (1999) demonstrated that WASp deficiency adversely
affected the development of immature thymocytes from
the CD4CD8 double-negative (DN) to the CD4+CD8+
double-positive (DP) stage. However, a significant thymic
developmental defect was not identified in the Snapper
et al. WAS knockout mouse strain. These latter results
were consistent with an in vivoWAS+/ competitive model
indicating minimal advantage for WASp-expressing cells
either in the thymus during transition from DN to DP
T cells, or in the spleen for NK cells (Westerberg et al.,
2008). Importantly, WAS knockout mice expressing a
WASp DVCA transgene exhibited severe impairment in
thymopoiesis, with a clear impairment in differentiation
of CD4CD8 thymocytes (Zhang et al., 2002).
We note that this studywas limited to iPSCs derived from
one WAS patient and one WAS genotype (1305 insG). The
WAS 1305 insG mutation is predicted to produce a WASp
lacking the C-terminal VCA domain. The aforementioned
publication by Zhang et al. (2002) suggested the possibility
that enforced expression of WASp DVCA functions in a
dominant-negative manner to suppress successful thymic
Tcell development. Althoughwewere not able to detect re-
sidual expression of the mutant frameshifted, truncated
WASp in WAS-iPSC-derived HPCs, it remains a possibility
that it exists at a very low level, and thus contributed to
our observed defective in vitro Tcell development. Thema-
jority of the experiments directly compared one corrected
WAS-iPSC clone with the mutant WAS-iPSC clone from
which it was derived; to convince ourselves that the
inability to generate T cells was not a clone-specific defect
but rather was due to non-functional WASp, we verified
the T cell development deficiency with two other WAS-
iPSC clones derived from the same donor fibroblasts (Fig-
ure 4C). Both the WAS2–12 transgene and the GFP reporter
distinguished the cWAS-iPSCs from the WAS-iPSCs. It is
conceivable that GFP expression, albeit at a low level, could
have affected the quantitative comparison between cWAS
andWAS.However, we note that the statistically significant
defects observed for NK and T cell development were quite
specific, not seen for example in derivation of endothelial146 Stem Cell Reports j Vol. 7 j 139–148 j August 9, 2016cells, hematopoietic progenitors (CD34+CD43+ or CD34+
CD43+CD45+), or CD5+CD7+ T cell precursors.
Somatic revertant mosaicism is a frequent finding in
WAS, identifiable in up to 10% of patients, with WASp-ex-
pressing cells arising in T, B, and/or NK cell lineages. The
identification of revertant WASp-expressing T cells in
WAS patients carrying either the 1305 insG or the closely
related 1305 delG mutation (also encoding WASp DVCA)
is a frequent finding (Lutskiy et al., 2008; Wada et al.,
2003). The revertant genotypes in these patients re-estab-
lish expression of a WASp including the VCA domains.
These data indicate that restoration of expression of a
WASp including the VCA domain, whether by intentional
gene correction (as done in the present study) or by rever-
sion, confers a strong selective advantage to T cells. It is
generally accepted that a strong selective advantage for
revertant cells operates at the level of mature peripheral
T cells in their transition, on exposure to antigen, from
naive to memory T cells. Our data, together with results
from some, but not all, of theWAS knockoutmousemodels
summarized above, suggest that an additional selective
advantage for corrected cells possibly exists at a much
earlier stage, during T cell development in the thymus.
This latter possibility, consistent with a polyclonal Tcell re-
ceptor (TCR) repertoire exhibited by revertant WAS cells
having the same revertant genotype (Wada et al., 2003),
would have implications both for somatic reversion and
for transplantation of corrected WAS-iPSC-derived T cell
precursors.EXPERIMENTAL PROCEDURES
iPSC Generation and Characterization
The WAS fibroblast cell line GM01598 (NIGMS Human Genetic
Cell Repository, Coriell Institute for Medical Research) was trans-
duced with pMXs retroviruses expressing OCT4, SOX2, KLF4,
NANOG, and c-MYC. iPSC colonies were subsequently identified
based on morphology and live-cell staining for Tra-1-60 and
Tra-1-81. Pluripotency was assayed by teratoma formation; animal
experimentation was overseen by the University of Texas Health
Science at Houston Animal Welfare Committee.
ZFN-Mediated Correction
ZFN plasmids (pVax15755 and pVax15724) targetedWAS intron 1
sequences 50-CCT TTGGGCCCA tga ctG TCATGAGGCAGgAAG
GAC-30 (spacer sequences in lower case). iPSCs were nucleofected
with ZFNs together with a donor construct which included wt
WASex2-12 cDNA linked to a GFP reporter via 2A peptide se-
quences, the bovine growth hormone pA sequences, followed by
a loxP-flanked puro-TK selection cassette.
Generation of Hematopoietic Progenitor Cells
hESC and hiPSC were dissociated using TrypLE Select and resus-
pended in APEL medium supplemented with BMP-4, VEGF, SCF,
and Y-27632. 5,000–7,000 cells were transferred into one well of a
96-well plate and centrifuged at 4803 g. Following 3–4 days of dif-
ferentiation, individual EBs were transferred onto OP9 stromal
cells and cultured for an additional 8 days in the presence of the
cytokines above.
Generation of NK Cells
Sorted CD34+CD43+ progenitors derived from each cell line were
seeded at 3 3 104 to 5 3 104 cells per well onto 24-well plates
pre-coated with live OP9-DL1. Cells were maintained in NK cell
differentiation medium including 15% heat-inactivated human
AB serum, SCF, IL-7, IL-15, Flt3 ligand, and IL-3 (first week only).
Cells were cultured in this system for 28–32 days.
T Cell Differentiation
The Tcell protocol was based on the protocol described by Timmer-
mans et al. (2009) with minor modifications. Briefly, day 12 spin
EBs were dissociated and cells were resuspended in minimum
essential medium alpha supplemented with 20% fetal bovine
serum, SCF, Flt3 ligand, and rhIL-7. Cellswere transferred onto sub-
confluent OP9-DL1 feeder layers. Every 5–7 days, cells were trans-
ferred on a fresh OP9-DL1 monolayer, for up to 6 weeks. Flow
cytometric analysis was performed on days 14, 21, 28, and 33,
plus or minus 2 days.
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